Page 33 - MemoriaCIBER-2018ENG

NANBIOSIS ICTS Platform
Coordinator: Jaume Veciana Miró
In 2018 NANBIOSIS renewed its accreditation as an “ICTS” (Singular Scientific and Technological Infrastructure). After the assessment of four years’ work of the ICTS and their strategic
plans, the Ministry of Science, Innovation and Universities passed the update of the National ICTS Map, including NANBIOSIS with the incorporation of a third node to the two founders (CIBER and CCMIJU). This third node is the Centro Andaluz de Nanomedicina y Biotecnología (BIONAND) in Malaga, which has brought Nanoimaging unit 28 into NANBIOSIS.
Furthermore, after the annual internal assessment of the NANBIOSIS units, one of
these left the ICTS in 2018 and, going on with the process of incorporating new internal units,unit 29 for synthesis of oligonucleotides, located in the IQAC-CSIC, joined platform 1 for production of biomolecules.
The NANBIOSIS web page has been designed to directly promote ground-breaking biomedical solutions, by means of which researchers and companies are provided with the integrated expertise of the NANBIOSIS units. Some of these solutions are being structured and others are already under way, with some success cases.
The most ambitious of these is the cascade characterisation of nanomedicines, which includes the services required to characterise the physical-chemical attributes and their in vitro and in vivo biological properties (immunology, toxicology and effectiveness), using suitable animal models. The video for dissemination
of NANBIOSIS (https://www.youtube.com/ watch?time_continue=3&v=vezgov-kc0g) specifically focuses on this biomedical solution.
The search for public or private external financing continues to be a priority. There has been a follow-up of cooperation schemes already started with companies and of national projects such as
BIOTAPES,from the RETOS-COLABORACIÓN programme, or European ones such as BERENICE (FP7) or DRIVE (H2020). In 2018 the European project known as SAFE-N-MEDTECH (H2020) was granted, with the aim of setting up an open-access platform based on online tools
for companies and reference laboratories, to interconnect capacities, knowledge, networks and services for development, testing, assessment, scale improvement and exploitation of medical and diagnostic devices on the market, based
on nanotechnology. The project is participated in by a further 27 partners apart from CIBER, and it will have wide-ranging participation of the NANBIOSIS units and of its organisational structure.
Funds has been obtained through the Pronanbiosis II project (Excellence Networks call) which enables taking on a person for daily management of NANBIOSIS as an ICTS and maintenance of the web page.
NANBIOSIS was presented at international bodies, national companies, foundations and public research organisations, and has been involved in partnering events for seeking associates such as Bio Europe (Berlin), Big Science Business Forum 2018 (Copenhagen), Brokerage event on Advanced Materials NMPB and the XI Conferencia Anual de las Plataformas Tecnológicas de Investigación Biomédica.
Among other activities we should stress the organisation by NANBIOSIS of a Forum in
Drug delivery and targeting and a Jornada de Nanotoxicidad in cooperation with Materplat and NanomedSpain, as well as the participation of NANBIOSIS in the MATERPLAT.
The third meeting of the Scientific Advisory Committee of NANBIOSIS was held, coinciding with the CIBER-BBN Annual Conference.
33
CIBER-BBN | ANNUAL REPORT 2018